TargetBeta
BTN3A1
butyrophilin subfamily 3 member A1 · also BT3.1, BTF5, CD277, BTN3.1 · Butyrophilins
1 program in company-led studies act on BTN3A1, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-BTN3A Agonistic Monoclonal Antibody ICT01rule | Ipsen | agonist | phase 3 | 32 running | – | NCIt |
Conditions their studies are in
- Hematologic Neoplasms, 1 program
- Leukemia, Myeloid, Acute, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Oct 15, 2027Anti-BTN3A Agonistic Monoclonal Antibody ICT01 · Ipsen · phase 3 · NCT04243499
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.